肾淀粉样变性 中国就医指南

Renal amyloidosis is a rare, systemic disorder characterized by the extracellular deposition of misfolded amyloid fibrils—primarily immunoglobulin light chains (AL type) or serum amyloid A protein (AA type)—within the kidney’s glomeruli, tubules, and interstitium. These insoluble, beta-pleated sheet aggregates disrupt normal renal architecture and function, leading to progressive proteinuria, nephrotic syndrome, and ultimately end-stage kidney disease if untreated. Pathogenesis hinges on abnormal protein folding and impaired clearance: in AL amyloidosis, clonal plasma cell dyscrasia produces excess monoclonal light chains that aggregate into amyloid; in AA amyloidosis, chronic inflammatory conditions (e.g., rheumatoid arthritis, tuberculosis, or familial Mediterranean fever) drive sustained overproduction of serum amyloid A, which fragments and deposits as amyloid in tissues. Less common forms include hereditary (ATTR, APOL1-related) and dialysis-related (β2-microglobulin) variants. Epidemiologically, renal amyloidosis accounts for ~1–5% of all cases of nephrotic syndrome in adults and is significantly underdiagnosed due to nonspecific early symptoms and reliance on tissue biopsy with Congo red staining and immunohistochemistry or mass spectrometry for definitive subtyping. Incidence is estimated at 5–10 new cases per million population annually in high-income countries; AL amyloidosis peaks in the sixth to seventh decades (median age 63), with a male predominance (M:F ≈ 1.5:1); AA amyloidosis occurs across broader age groups but correlates strongly with duration and severity of underlying inflammation. Key risk factors include monoclonal gammopathy of undetermined significance (MGUS), multiple myeloma, chronic infections (e.g., osteomyelitis, HIV), autoimmune diseases, and genetic predispositions (e.g., SAA1 polymorphisms). Quality of life is profoundly impacted: patients commonly experience debilitating fatigue, edema-related mobility limitations, recurrent infections due to hypoalbuminemia and immunoglobulin loss, thromboembolic events, and psychological distress—including anxiety and depression—stemming from diagnostic delays, treatment complexity, and uncertain prognosis. As renal function declines, dietary restrictions, frequent clinic visits, and eventual dialysis or transplant candidacy further erode autonomy and social participation. Early diagnosis remains critical—not only to preserve kidney function but also to address systemic involvement (e.g., cardiac, hepatic, or neurologic amyloid), which dictates overall survival. Without timely intervention, median survival in AL amyloidosis with renal involvement is <2 years; with modern risk-adapted therapy, 5-year survival now exceeds 60%. Multidisciplinary care involving nephrology, hematology, cardiology, and pathology is essential for optimal outcomes.

# 肾淀粉样变性治疗方案与费用明细（肾内科）

一、非手术/保守治疗方案

适用人群：AL型早期、ATTR野生型、轻度蛋白尿（<3g/d）、eGFR ≥45 mL/min/1.73m²者

• •基础支持治疗：限盐饮食、ACEI/ARB降蛋白尿、利尿剂、纠正贫血及钙磷代谢紊乱

• •靶向药物治疗（AL型）：硼替佐米+地塞米松±环磷酰胺方案（6–12周期）

• •新型疗法（ATTR型）：氯苯唑酸软胶囊（口服）

二、核心介入/根治性方案

适用条件：AL型高危、浆细胞克隆明确、无严重心功能不全（LVEF≥40%）、年龄≤70岁

• •自体造血干细胞移植（ASCT）

- 全套费用（动员、采集、回输、粒缺期监护）：22.5万–34.8万元（公立三甲医院收费）

三、晚期/并发症/耐药方案

• •透析过渡+多学科管理（心肾联合衰竭、胃肠道出血）：年均费用15.6万–22.3万元（含HD/腹透、营养支持、抗凝调整）
• •难治性AL型联合达雷妥尤单抗：年费用38.2万–45.6万元（超适应症使用，需伦理审批）

方案快速选择指南

✅ 预算有限（≤5万元/年）：优选ACEI/ARB+支持治疗+定期随访 ✅ 中高预算（10–30万元）+AL型初治：硼替佐米方案或ASCT评估 ✅ ATTR型确诊+长期用药需求：氯苯唑酸（医保优先） ✅ eGFR<15+多器官受累：启动透析联合姑息支持，避免激进化疗